Cereno Scientific strengthens R&D with recruitment of Medical Director
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that Tatiane Abreu Dall’Agnol has joined the company as Medical Director. She will be part of the company’s R&D team and report to Björn Dahlöf, Chief Medical Officer (CMO).“I am pleased to welcome Tatiane to the team as we enter a significant phase for Cereno with intensified operations in our preclinical and clinical development programs. Tatiane has been part of our team in a consultancy capacity during the last two years and will in her